S
Synthorx
Biotech & Life Sciences · San Diego, United States · Founded 2014 · IPO 2018
Biotechnology company using synthetic biology to synthesize solutions MoreLess
Synthorx is a biotechnology company specializing in the design and development of protein therapeutics, known as Synthorins, aimed at treating cancer and autoimmune disorders. The company leverages a novel DNA base pair technology to create optimized and tailored medicines, representing a significant advancement in protein design. Synthorx primarily serves patients suffering from severe diseases, focusing on improving their quality of life through innovative medical solutions. Operating in the biopharmaceutical market, Synthorx's business model involves extensive research and development, followed by clinical trials to validate the efficacy of their therapeutics. Revenue is generated through the commercialization of these therapeutics, partnerships, and collaborations with other pharmaceutical companies. The company has successfully raised significant capital through public offerings and private funding rounds, enabling continuous innovation and expansion of their therapeutic pipeline.
Keywords: biotechnology, protein therapeutics, cancer treatment, autoimmune disorders, DNA base pairs, Synthorins, biopharmaceutical, clinical trials, medical innovation, tailored medicines.
Talent graph
Synthorx's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Synthorx has talent and traffic
team presence
Patent intelligence
$36M patent portfolio · 29 active families
Where Synthorx concentrates vs peers
Each axis is a top-10 topic across Synthorx and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Synthorx
An AI-synthesized read of the highest-engagement posts about Synthorx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synthorx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.